NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

189.43B

Vuru Grade

69.64/100

Current Price

$79.55
+0.00 (+0.00%)

Growth Price

$56.04
Overvalued by 29.55%

Stability Price

$14.58
Overvalued by 81.68%

Company Metrics

  • P/E 28.40
  • P/S 3.81
  • P/B 2.61
  • EPS 2.80
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.34 %
  • Avg. Vol. 1.48M
  • Shares 2.38B
  • Market Cap. 189.43B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Novartis AG (ADR) (NYSE:NVS): Reviewing Earnings Estimates
Post Registrar - Jul 19, 2016
Novartis AG (ADR) (NYSE:NVS) soared 0.51% or +0.42 points during previous trade after opening at the price of $81.92, a total of 1.58M shares exchanged hands compared with its average trading volume of 1.71M shares.
Novartis AG (ADR) 2Q Earnings: Here's What To Expect? - Bidness ETC
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
TCC - Aug 16, 2016
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
TCC - Aug 8, 2016
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
Business Finance News - May 20, 2016
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
How Many Heart Failure Deaths Can Novartis AG (ADR) (NYSE:NVS) Entresto Reduce?
Market Exclusive - Jun 23, 2016
A fresh analysis of Novartis AG (ADR) (NYSE:NVS) drug Entresto has shown that it can significantly reduce heart failure deaths.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Business Finance News - Nov 23, 2015
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
Business Finance News - May 4, 2016
As the merger and acquisition (M&A) spree is booming, multiple pharmaceutical companies have put Medivation Inc. (NASDAQ:MDVN) on the top of their acquisition list.
Novartis AG (ADR) Aiming to Target Biosimilar Market by 2020
Business Finance News - Jun 20, 2016
By 2020, Novartis AG (NYSE:NVS) plans to launch a number of biosimilar versions of the blockbuster drugs in order to enter multiple therapeutic markets.
What Next for Novartis AG (ADR) After Today's Gap Down?
Press Telegraph - 16 hours ago
The stock of Novartis AG (ADR) (NYSE:NVS) gapped down by $0.03 today and has $73.21 target or 8.00% below today's $79.58 share price.
Guyasuta Investment Advisors INC Increased Novartis Ag Adr (NYSE:NVS) by $8.14 ... - Consumer Eagle
Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis ... - Benzinga